(19)
(11) EP 2 209 377 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.09.2018 Bulletin 2018/36

(45) Mention of the grant of the patent:
02.05.2018 Bulletin 2018/18

(21) Application number: 08846682.6

(22) Date of filing: 06.11.2008
(51) International Patent Classification (IPC): 
A01N 45/00(2006.01)
A61K 31/592(2006.01)
C12Q 1/02(2006.01)
A61P 1/18(2006.01)
G01N 33/50(2006.01)
 A61K 31/00(2006.01)
A61K 31/593(2006.01)
A61P 1/16(2006.01)
G01N 33/82(2006.01)
(86) International application number:
PCT/US2008/082691
(87) International publication number:
WO 2009/061961 (14.05.2009 Gazette 2009/20)

(54)

USE OF VITAMIN D RECEPTOR AGONISTS AND PRECURSORS TO TREAT FIBROSIS

VERWENDUNG VON VITAMINREZEPTORAGONISTEN UND VORSTUFEN FÜR DIE BEHANDLUNG VON FIBROSE

UTILISATION D'AGONISTES ET DE PRÉCURSEURS DE RÉCEPTEURS DE LA VITAMINE D POUR TRAITER LA FIBROSE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 06.11.2007 US 985972 P

(43) Date of publication of application:
28.07.2010 Bulletin 2010/30

(73) Proprietors:
  • The Salk Institute For Biological Studies
    La Jolla, CA 92037-1099 (US)
  • University of Sydney
    NSW 2000 (AU)

(72) Inventors:
  • EVANS, Ronald, M.
    La Jolla CA 92037 (US)
  • DOWNES, Michael
    San Diego CA 92117 (US)
  • LIDDLE, Christopher
    Tura Beach New South Wales 2548 (AU)

(74) Representative: Harrison IP Limited 
3 Ebor House Millfield Lane
Nether Poppleton, York YO26 6QY
Nether Poppleton, York YO26 6QY (GB)


(56) References cited: : 
EP-A1- 0 682 879
US-A1- 2005 124 591
US-A1- 2006 135 610
 US-A1- 2005 009 793
US-A1- 2006 074 109
US-A1- 2006 240 150
   
  • TAN ET AL: "Therapeutic role and potential mechanisms of active Vitamin D in renal interstitial fibrosis" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB LNKD- DOI:10.1016/J.JSBMB.2006.11.011, vol. 103, no. 3-5, 15 March 2007 (2007-03-15), pages 491-496, XP022275094 ISSN: 0960-0760
  • TAN XIAOYUE ET AL: "Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy" JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 17, no. 12, December 2006 (2006-12), pages 3382-3393, XP002605885 ISSN: 1046-6673
  • GASCON-BARRE ET AL.: 'The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells.' HEPATOLOGY vol. 37, no. 5, 2003, pages 1034 - 1042
  • OMARY ET AL.: 'The pancreatic stellate cell: a star on the rise in pancreatic diseases.' JOURNAL OF CLINICAL INVESTIGATION vol. 117, no. 1, January 2007, pages 50 - 59
  • ZEHNDER ET AL.: 'Expression of 25-hydroxyvitamin D3-lalpha-hydroxylase in the human kidney.' J AM SOC NEPHROL vol. 10, 1999, pages 2465 - 2473
  • JOHNSON ET AL.: 'The activated mesangial cell: a glomerulat myofibroblast?' JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY vol. 2, no. SUP 02, 1992, pages S190 - S197
  • CAO ET AL.: 'Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells.' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 279, no. 6, 2004, pages 4292 - 4304
  • J A MCCARROLL: "Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis", GUT, vol. 55, no. 1, 1 January 2006 (2006-01-01), pages 79-89, XP055395056, UK ISSN: 0017-5749, DOI: 10.1136/gut.2005.064543
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).